Journal article
ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic
Abstract
Replicating viruses for the treatment of cancer have a number of advantages over traditional therapeutic modalities. They are highly targeted, self-amplifying, and have the added potential to act as both gene-therapy delivery vehicles and oncolytic agents. Parapoxvirus ovis or Orf virus (ORFV) is the prototypic species of the Parapoxvirus genus, causing a benign disease in its natural ungulate host. ORFV possesses a number of unique properties …
Authors
Rintoul JL; Lemay CG; Tai L-H; Stanford MM; Falls TJ; de Souza CT; Bridle BW; Daneshmand M; Ohashi PS; Wan Y
Journal
Molecular Therapy, Vol. 20, No. 6, pp. 1148–1157
Publisher
Elsevier
Publication Date
June 2012
DOI
10.1038/mt.2011.301
ISSN
1525-0016
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsCell Line, TumorCytokinesDisease Models, AnimalFemaleGenetic TherapyGenetic VectorsHumansImmunity, InnateKiller Cells, NaturalLungLung NeoplasmsMelanoma, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasmsOncolytic VirotherapyOncolytic VirusesOrf virusSpleenTumor BurdenVirus ReplicationXenograft Model Antitumor Assays